EV71 vaccine, an invaluable gift for children
Authors:
Open Access
- 31 October 2014
- journal article
- review article
- Published by Wiley in Clinical & Translational Immunology
- Vol. 3 (10) , e28
Abstract
Enterovirus 71 (EV71) is a major pathogen for severe hand, foot and mouth disease (HFMD). Development of vaccines against EV71 would be the most effective approach to prevent the EV71 outbreak. Research and development (R&D) of EV71 vaccine was carried out in several Asian countries. Currently three companies in mainland China have completed Phase III clinical trials of inactivated EV71 whole‐virus vaccines, whereas the other two companies have completed Phase I clinical trials separately in Taiwan and in Singapore. Results from those clinical trials have indicated high safety and immunogenicity of EV71 vaccine. Protective efficacies were over 90% on EV71‐associated HFMD and over 80% on other EV71‐associated diseases. In this paper, we summarize the results from three EV71 vaccine Phase III clinical trials and discuss the challenges of incorporating EV71 vaccine into Expanded Program on Immunization (EPI) in countries with EV71 epidemics.Keywords
This publication has 21 references indexed in Scilit:
- Hand, foot, and mouth disease in China, 2008–12: an epidemiological studyThe Lancet Infectious Diseases, 2014
- Efficacy, Safety, and Immunogenicity of an Enterovirus 71 Vaccine in ChinaNew England Journal of Medicine, 2014
- An Inactivated Enterovirus 71 Vaccine in Healthy ChildrenNew England Journal of Medicine, 2014
- Progress on the research and development of inactivated EV71 whole-virus vaccinesHuman Vaccines & Immunotherapeutics, 2013
- Immunogenicity, Safety, and Immune Persistence of a Novel Inactivated Human Enterovirus 71 Vaccine: A Phase II, Randomized, Double-Blind, Placebo-Controlled TrialThe Journal of Infectious Diseases, 2013
- Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2013
- Progress on the research and development of human enterovirus 71 (EV71) vaccinesFrontiers of Medicine, 2012
- Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, double-blind, Phase I clinical trialVaccine, 2012
- Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccinesVaccine, 2011
- Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71Archives of Virology, 2011